{
  "source": "PA-Med-Nec-Motegrity.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2167-7\nProgram Prior Authorization/Medical Necessity\nMedication Motegrity® (prucalopride)\nP&T Approval Date 6/2019, 6/2020, 6/2021, 6/2022, 11/2022, 6/2023, 6/2024\nEffective Date 9/1/2024\n1. Background:\nMotegrity (prucalopride) is indicated for the treatment of chronic idiopathic constipation\nin adults. Physicians and patients should periodically assess the need for continued\ntreatment with Motegrity. Linzess® (linaclotide) is indicated for the treatment of chronic\nidiopathic constipation and irritable bowel syndrome with constipation in adults and the\ntreatment of functional constipation (FC) in pediatric patients 6 to 17 years of age..\nLinzess has a black box warning regarding the risk of serious dehydration in pediatric\npatients less than 2 years of age and in patients with known or suspected mechanical\ngastrointestinal obstruction. Amitiza®* (lubiprostone) is indicated for the treatment of\nchronic idiopathic constipation and irritable bowel syndrome with constipation in adults\nand for the treatment opioid-induced constipation (OIC) in adult patients with chronic,\nnon-cancer pain, including patients with chronic pain related to prior cancer or its\ntreatment who do not require frequent (e.g., weekly) opioid dosage escalation.\nThis program is intended to encourage the use of lower cost alternatives and requires a\nmember to try lower cost alternatives before providing coverage for Motegrity.\n2. Coverage Criteriaa:\n1. Initial Authorization\na. Motegrity will be approved based on both of the following criteria:\n1) Diagnosis of chronic idiopathic constipation\n- AND-\n2) History of failure, contraindication, or intolerance to both of the following:\na) Linzess\nb) lubiprostone (generic Amitiza)\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Motegrity will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Motegrity therapy\nAuthorization ",
    "tion will be issued for 12 months\n2. Reauthorization\na. Motegrity will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Motegrity therapy\nAuthorization will be issued for 12 months\n© 2024 UnitedHealthcare Services Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Brand only Amitiza may be excluded from benefit coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n• Notification/Prior Authorization may be in place\n4. References:\n1. Amitiza [package insert]. Lexington, MA: Takeda pharmaceuticals America, Inc;\nNovember 2020.\n2. Linzess [package insert]. North Chicago, IL: AbbVie, Inc.; June 2023.\n3. Motegrity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.;\nNovember 2020.\nProgram Prior Authorization/Medical Necessity - Motegrity\nChange Control\nDate Change\n6/2019 New program\n6/2020 Annual review.\n6/2021 Annual review. Updated references.\n6/2022 Annual review. Updated references.\n11/2022 Review. The black box warning of Linzess changed the\ncontraindication from patients less than 18 to patients less than 2 years\nof age therefore removed the age bypass for Amitiza.\n6/2023 Clarification to change control from 11/2022 - The black box warning\nof Linzess changed the contraindication from patients less than 18 to\npatients less than 2 years of age therefore removed the age bypass of\nage less than or equal to 17. Removed OTC step and added step through\ngeneric Amitiza.\n6/2024 Annual review. Updated background section and references.\nReferenced bra",
    "erefore removed the age bypass of\nage less than or equal to 17. Removed OTC step and added step through\ngeneric Amitiza.\n6/2024 Annual review. Updated background section and references.\nReferenced brand Amitiza exclusion.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}